- 1 A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of
- 2 locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of
- 3 America
- 4 Jin Zhou¹, Yukai Tang¹, Geli Li^{2*}
- ⁵ ¹Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan,
- 6 China
- 7 ²Department of Oncology, Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China
- 8 [¶]1st set of equal contributors.
- 9 *Corresponding author
- 10 E-mail: 19165664057@163.com
- 11
- 12
- 13
- 15
- 14
- 15
- 16
- 17
- 18
- 10
- 19
- 20
- 21

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24 Abstract:

25	Background: Nivolumab in combination with chemotherapy significantly improves survival in
26	patients with gastric/gastroesophageal junction (G/GEJ)/esophageal adenocarcinoma. The purpose
27	of this study was to evaluate the cost-effectiveness of Nivolumab plus chemotherapy for
28	G/GEJ/esophageal adenocarcinoma.
29	Methods: A Markov model was developed on the basis of the US healthcare payers' perspectives.
30	We estimated the costs and summarised their effectiveness as quality-adjusted life-years
31	(QALYs). One-way and probabilistic sensitivity analyses were conducted to explore the impact of
32	uncertainties on the cost-effectiveness's results.
33	Results: The incremental cost-effectiveness ratios (ICER) for Nivolumab plus
34	chemotherapy(\$149636.97,1.24QALYs) verus chemotherapy(\$13941.06,0.75QALYs) is
35	\$135695.91 and the QALYs is 0.49.
36	Conclusions: Evidence suggests that Nivolumab plus chemotherapy a for the first-line treatment
37	of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma may be not a
38	cost-effective choice.
39	Keywords: Cost-Effectiveness; Nivolumab; metastatic gastric/GEJ/oesophageal adenocarcinoma;
40	Markov model
41	
42	
43	

45

46 1. Background

47 Gastric/gastroesophageal junction(G/GEJ)/oesophageal adenocarcinoma can be regarded as a relatively common cancer worldwide, and its incidence is increasing day by day. Nowadays, 48 49 gastric cancer is the fifth most common cancer in the world, and its fatality rate ranks the third 50 among all cancers. From the perspective of geographical distribution, the incidence has increased 51 significantly in east Asia in recent years, as has North America (1). At present, surgery is still the 52 preferred treatment for G/GEJ/oesophageal adenocarcinoma. However, the prognosis is bleak and 53 the postoperative recurrence rate reaches 50%-70% (2, 3). For those patients with unresectable 54 advanced stage, other methods can only be sought.

In recent years, many studies have focused on improving the prognosis of this group of patients. At present, fluorouracil, platinum and paclitaxel are the main chemotherapy drugs for advanced G/GEJ/oesophageal adenocarcinoma with negative HER-2, but their therapeutic effect is not optimistic, and the survival time of most patients receiving chemotherapy is not more than 1 year (4-6). Besides, after the use of targeted therapy combined with chemotherapy for these patients, their survival was not significantly improved compared with chemotherapy (7-10).

Nivolumab is a PD-1 inhibitor. As PD-L1 is expressed more obviously in tumor cells and tumor immune cells than in normal cells, PD-1 inhibitor has been gradually promoted to a higher position in tumor therapy. Nivolumab has shown good efficacy in the treatment of many cancers such as non-small cell lung cancer and renal cell carcinoma (11, 12). Therefore, the Checkmate 649, a phase 3 trial, has been carried out,in which researchers recruited a group of advanced, unresectable and HER-2 negative patients and randomly divided them into two groups. In addition

67	to the analysis of all patients, PD-L1 CPS>5 patients were singled out for follow-up
68	analysis. Then, the prognosis of the two groups of patients was compared between the
69	combination chemotherapy with Nivolumab and chemotherapy alone. In the Result, For patients
70	with PD-L1 CPS≥5, median OS improvement was 3 months (14.4 months [95% CI 13.1 to
71	16.2]vs 11.1 month [10.0 to 12.1]); Median PFS was 7.7 months (95% CI 7.0 to 9.2) for
72	combination chemotherapy with Nivolumab compared with 6.05 months (5.0 to 6.9) for
73	chemotherapy. For all randomized patients, the median OS was 13.1 months (IQR, 6.7 to 19.1) in
74	the Nivolumab group and 11.1 months (5.8 to 16.1) in the chemotherapy group. In conclusion,
75	Compared with chemotherapy alone, Nivolumab combined with chemotherapy significantly
76	improved patient survival, especially in patients with PD-L1 CPS >5 (13).
77	A cost-benefit analysis is necessary before a new drug becomes an approved method of
78	treatment for many patients. Hence, in this study, based on the results of the Checkmate649
79	clinical trial, we established an economic model to evaluate the cost-effectiveness of Nivolumab
80	in combination with chemotherapy in G/GEJ/oesophageal adenocarcinoma.
81	
82	
83	
84	
85	
86	
87	
88	

89

90 2. Materials and Methods

- 91 2.1 Population
- 92 CheckMate 649 is a randomized phase 3 trial involving 1581 patients from From March 2017
- through April 2019 in all over the world. Median progression-free survival (7.7 months [95% CI
- $7 \cdot (0 9 \cdot 2)$ was significantly longer in the nivolumab plus chemotherapy group than in the
- 95 chemotherapy group (6.05 months [95% CI 5.6–6.9]) in patients with PD-L1 CPS ≥5, as was median
- 96 overall survival analysis (14.4 months [95% CI 13.1-16.2] vs 11.1 months [10.0-12.1],
- 97 respectively) in patients with PD-L1 CPS \geq 5).Our data were based on clinical characteristics of
- 98 CheckMate 649 subjects aged 18 years or older with previously untreated, unresectable advanced
- 99 or metastatic gastric, GEJ, or oesophageal adenocarcinoma, regardless of PD-L1 expression.


100 We focused on the third phase of the CheckMate 649 study. In the total number of people in this trial, there are 955 patients with PD-L1 CPS >5. Among them, 473 participants were in the 101 102 experimental group(Nivolumab chemotherapy)and 482 plus in the control 103 group(chemotherapy).We conducted a cost-effectiveness analysis for the Nivolumab plus chemotherapy group and chemotherapy group to provide a foundation for their different treatment. 104 105 The research methods refer to the consolidated health economic evaluation reporting standards

106 (CHEERS)(see Supplementary Information S1).

107 2.2 The Model's Structure

108 The study used TreeAge Software 2021 (TreeAge Software, Inc, Williamstown, 109 Massachusetts) to programme a multi-state Markov model. The purpose was to evaluate the 110 cost-effectiveness of Nivolumab plus chemotherapy and chemotherapy in patients with untreated,

111 unresectable advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma. This was due to 112 the Markov model being able to provide more flexible modelling assumptions.(14) The multiple 113 health states include PFS, progressive disease state (PD) and death. Assuming that patients in a 114 certain state only make one state transition in a cycle, once the patients are in the PD state, they 115 cannot return to the PFS state. Similarly, the patients in the dead state cannot transition to other states. The specific transition relationships are shown in Figure 1. We assumed that all the patients 116 were in a PFS healthy state at the model's initial stage. The patients were treated with Nivolumab 117 118 plus chemotherapy or chemotherapy according to their groupings. When the disease progresses, the follow-up treatment plan in the CheckMate 649 clinical trial is used for treatment until the 119 120 patient's death.



121 122

Figure1. Markov state transition model.

We developed a Markov model to simulate the patient's entire life course and evaluate the cost and effectiveness of first-line therapy for patients with advanced/metastatic gastric, GEJ, or oesophageal adenocarcinoma.In the CheckMate 649 clinical trial, the median survival time of the experimental group was 14.4 months, the control group was 11.1 months, and the overall time of the study is approximately 2 years. The effect of immunotherapy has a delayed effect and may continue to work beyond the treatment period. It should be analyzed from long-term data to avoid inaccuracy and uncertainty of results(15, 16).As the result of that, with reference to the dosing

130 cycle of the CheckMate 649 clinical trial, we set the cycle of the Markov model to three weeks and the time range was 10 years. Approximately 99% of patients were in the absorption state.(17) 131 132 A half-circle correction was conducted to simulate the transfer process more accurately. 133 Simultaneous simulation analysis of the cost and utility is performed to estimate the cumulative 134 total cost and health outcomes within the cohort's time frame.(18, 19) The research was based on the American payers' perspectives, with a 3% discount on costs and utilities.(20) According to the 135 World Health Organization, ICER is acceptable when it is below three times GDP per capita(21). 136 137 This study will use three times of the United States's triple GDP per capita in 2021(\$69219.5) as 138 the threshold(https://fred.stlouisfed.org/series/A939RC0Q052SBEA).The WTP is assumed to be \$207659. The research indicators include the costs, life-years (LYs), quality-adjusted 139 140 life-years(QALYs), and the incremental cost-effectiveness ratios (ICERs).

141 2.3 The Model's Survival and Progression Risk Estimates

142 The original data for constructing the model were obtained from the CheckMate 649 clinical 143 trial. When some data were unavailable, we referred to the related published literature. The 144 GetData Graph Digitiser (version 2.26; http://getdata-graph-digitizer.com/download.php) was 145 used to extract the Kaplan-Meier curve's data of the PFS and OS in the Nivolumab plus 146 chemotherapy group and the chemotherapy group. We also referred to the algorithm of Guvot et al. who refers to the pseudo-individual patient's data reconstructed by R software (version 4.1.0; 147 148 https://www.r-project.org/).(22) This was combined with the Akaike Information Criterion (AIC) 149 and the Bayesian Information Criterion(BIC) to select the Log-logistic distribution that fitted the 150 survival curve for Nivolumab plus chemotherapy and chemotherapy respectively after the reconstruction(eTable 1).(23) The distribution has a higher flexibility and estimated 151

152 correlations.(24, 25)


|--|


Table 1 Base-case Analysis


	Nivolumab plus	
Parameters	chemotherapy	Chemotherapy
QALYs	0.75	0.27
Total cost \$	13941.06	17565.97
ICER \$/QALYb	276799.67	
WTP \$/QALY	190239	

154

155







159	During the follow-up, the CheckMate 649 trial used the Gastric Cancer Subscale (GaCS) to
160	compare quality of life after Nivolumab plus chemotherapy vs chemotherapy as the first-line
161	treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal
162	adenocarcinoma.the average health utility (0.797 for PFS and 0.577 for PD) of the patients with
163	gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma in the PFS and PD
164	was obtained by previously published study(26). The top three incidence adverse events(AEs)
165	with grade 3 or above were selected in Nivolumab plus chemotherapy (nivolumab [360 mg every
166	3 weeks or 240 mg every 2 weeks]-pluschemotherapy[XELOX every 3 weeks or FOLFOX every
167	2 weeks], nivolumab-plus-ipilimumab) and chemotherapy to be considered to evaluate the loss of
168	the health utility caused by the three to five adverse events(AEs) for simplifying the
169	calculation. The top three incidence adverse events(AEs) with grade 3 or above in Nivolumab plus
170	chemotherapy and chemotherapy are Neutropenia(14%),Decreased platelet
171	count(8%),Proteinuria(5%),Increased blood bilirubin(5%), Increased γ -glutamyltransferase(5%)
172	and Palmar-plantar erythrodysaesthesia syndrome(12%), Hypertension(6%), Increased aspartate
173	aminotransferase (5%), respectively.
174	The costs are reported in 2021 US dollars (US $1.0 = CNY + 6.38$). Only the direct costs of
175	the medical expenses were considered. This included the cost of the drugs, subsequent treatment
176	costs, management costs, follow-up costs, laboratory examination costs, and the major adverse
177	reactions with grade 3 or above had the top three incidence rates according to CheckMate 649
178	trial.
179	The drug prices we selected local hospital prices or the price obtained by consulting with the

180 drug supplier. The estimated cost of each drug during the set period is listed in Table 2. The

181	probability that different treatment groups intend to receive different follow-up treatment and the							
182	treatment mode of specific subsequent therapies(systemic therapy other than PD-(L)1 inhibitors,							
183	local regional th	nerapy, radiation	therapy, sur	rgery, PD-(L)1 inhibitors)	are deriv	ved from	
184	CheckMate 649 tr	ial.						
185	Table 2 Model	parameters: baseli	ne values, rar	nges, and distr	ibutions for sen	sitivity an	alysis.	
186			Main mod	lel parameters				
187 188	Table 2 Model para Main model paran	rameters: baseline s	values, range	s, and distribu	tions for sensiti	vity analy	sis.	
	Variable		Ra	nge				References
	(Group:CPS>5 patients)	Baseline value	Minimum	C	Distribution	Mean	Standard deviation	
	Parameter survival							
	distribution							
	log-logistic PFS	Shape=1.648147						11000
	of N+C	Scale=8.546154	-	-	-	-	-	Model fitting
	log-logistic OS	Shape=1.6508						Madal fitting
	of N+C	Scale=14.4888	-	-	-	-	-	Model fitting
	log-logistic PFS	Shape=1.6508	-	-	_	-	_	Model fitting
	of C	Scale=14.4888						Widder Humo
	log-logistic OS	Shape=1.7398	-	-	-	-	-	Model fitting
	of C	Scale=10.546		D .1.6	• •			
	Risk for main adverse events Nivolumab plus chemotherapy group							
	Neutropenia	0.15	0.12	Nivol	umab plus chemotherap Beta	0.15	0.03	Checkmate-649
	Neutrophil				Bela			
	count decreased	0.11	0.088	0.132	Beta	0.11	0.022	Checkmate-649
	Anaemia	0.07	0.056	0.084	Beta	0.07	0.014	Checkmate-649
	Diarrhoea	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649
					Chemotherapy gro	-		
	Neutropenia	0.06	0.048	0.072	Beta	0.06	0.012	Checkmate-649
	Neutrophil count decreased	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
	Anaemia	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
	Diarrhoea	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
				H	ealth utility sc	ores		
	Utility of PFS	0.797	0.6376	0.9564	Beta	0.797	0.1594	[2]
	Utility of PD	0.577	0.4616	0.6924	Beta	0.577	0.1154	[2]

			D	rug cost, \$/pe	er cycle		
Nivolumab-3w	9957.15	7965.72	11948.58	Gamma	9957.15	1991.43	Drugs
Oxaliplatin-3w	521.82	417.456	626.184	Gamma	521.82	104.364	Drugs
Capecitabine-3w	183.3	146.64	219.96	Gamma	183.3	36.66	Drugs
Nivolumab-2w	6638.1	5310.48	7965.72	Gamma	6638.1	1327.62	Drugs
Oxaliplatin-2w	341.19	272.952	409.428	Gamma	341.19	68.238	Drugs
Leucovorin-2w	185.184	148.1472	222.2208	Gamma	185.184	37.0368	Drugs
Fluorouracil-2w	43.62624	34.90099	52.35149	Gamma	332.148	66.42962	Drugs
Radiotherapy	8998.72	6,636.09	13,160.22	Gamma	8998.72	1799.744	[4]
Surgery	20982	10490	41960	Gamma	20982	4196.4	[7]
Paclitaxel	726.57	581.256	871.884	Gamma	726.57	145.314	Drugs
Docetaxel	215.595	172.476	258.714	Gamma	215.595	43.119	Drugs
Carboplatin	165.51	132.408	198.612	Gamma	165.51	33.102	Drugs
Cisplatin	17.064	13.6512	20.4768	Gamma	17.064	3.4128	Drugs
Ramucirumab	143731	114984.8	172477.2	Gamma	143731	28746.2	Drugs
Pembrolizumab	10739.54	8591.632	12887.45	Gamma	10739.5	2147.908	Drugs
				nditures on m			
			•		,		
				_			keynote590 [
Neutropenia	1043	834.4	1251.6	Gamma	1043	208.6	
							Reaction Tab
Neutrophil		272.0	550.2	C	ACC	02.2	keynote590 E
count decreased	466	372.8	559.2	Gamma	466	93.2	Decetion Tel
							Reaction Tab
							kovpoto500 F
Anaemia	1654	1323.2	1984.8	Gamma	1654	330.8	keynote590 E
Andenna	1034	1323.2	1904.0	Gaiiiiia	1034	550.8	Departion Tab
							Reaction Tab
							keynote590 E
Diarrhoea	3339.64	2671.712	4007.568	Gamma	3339.64	667.928	Keynole030 L
Diarmoea	5557.04	20/1./12	1007.500	Gainina	5557.04	007.920	Reaction Tab
Follow-up per	59.2	47.36	71.04	Gamma	59.2	11.84	[8]
cycle		17.50	/ 1.0 1	Guilling	09.2	11.01	[0]
Laboratory per	157.5	126	189	Gamma	157.5	31.5	[9]
cycle			/		-0,.0	•	L* J
Administration	69.81	55.848	83.772	Gamma	69.81	13.962	[8]
per cycle							r - 1
				sutility due			
Neutropenia	-0.09	-0.072	-0.108	Beta	-0.09	-0.018	[10]
Neutrophil	-0.26	-0.208	-0.312	Beta	-0.26	-0.052	
count decreased							54.03
Anaemia	-0.073	-0.0584	-0.0876	Beta	-0.073	-0.0146	[10]

Diarrhoea	-0.05	-0.04	-0.06	Beta	-0.05	-0.01	[10]
			Risl	k for Subsequ	uent therapy		
			И	Nivolumab plus chemo	otherapy group		
Radiotherapy	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649
Surgery	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Paclitaxel	0.18	0.144	0.216	Beta	0.18	0.036	Checkmate-649
Docetaxel	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Fluorouracil	0.09	0.072	0.108	Beta	0.09	0.018	Checkmate-649
Capecitabine	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
Oxaliplatin	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649
Carboplatin	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Cisplatin	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Ramucirumab	0.1	0.08	0.12	Beta	0.1	0.02	Checkmate-649
Nivolumab	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Pembrolizumab	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
				Chemotherap	oy group		
Radiotherapy	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649
Surgery	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Paclitaxel	0.21	0.168	0.252	Beta	0.21	0.042	Checkmate-649
Docetaxel	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649
Fluorouracil	0.14	0.112	0.168	Beta	0.14	0.028	Checkmate-649
Capecitabine	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Oxaliplatin	0.06	0.048	0.072	Beta	0.06	0.012	Checkmate-649
Carboplatin	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Cisplatin	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
Ramucirumab	0.1	0.08	0.12	Beta	0.1	0.02	Checkmate-64
Nivolumab	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-64
Pembrolizumab	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-64

189

190 The calculated drug dose are based on the actual clinical trials. In the Nivolumab plus 191 chemotherapy group, the patients received 360 mg of Nivolumab every 3 weeks or 240 mg every 192 2 weeks and chemotherapy (XELOX [capecitabine 1000 mg/m2 twice daily, days 1-14 and oxaliplatin 130 mg/m², day 1, every 3 weeks] or FOLFOX [leucovorin 400 mg/m2, day 1, 193 194 fluorouracil 400 mg/m², day 1 and 1200 mg/m², days 1–2, and oxaliplatin 85 mg/m², day 1, every 2 weeks]). In the chemotherapy group, the patients received chemotherapy alone. We 195 assumed that the average body surface area was 1.68 m².(27)When patients disease progressed, we 196

197	assumed that all patients who disease progressed had follow-up treatment. It is important to note
198	that the systemic therapy other than PD-(L)1 inhibitors in the subsequent therapies for advanced
199	Gastric cancer, which we chose based on the NCCN 2022.1 guideline, is oxaliplatin, leucovorin
200	plus fluorouracil therapy(oxaliplatin 85 mg/m2 IV on day 1, Leucovorin 200 mg/m2 IV on day
201	1,2,fluorouracil 2600 mg/m2 IV continuous infusionover 24 hours on day1).
202	2.5 Sensitivity Analyses
203	A one-way sensitivity analysis was performed to explore the influence of uncertain parameters on
204	the ICER.
205	Each parameter was independently changed by assuming $\pm 20\%$ of the expected value to determine
206	the obvious influence on decision-making.
207	Probabilistic analysis (PSA) was used to randomly sample all the parameters from a specified
208	distribution to further explore the uncertainty and relevance of the model's parameters. According
209	to the parameter type, we selected the appropriate distribution for each uncertain parameter: the
210	cost of the adverse reactions to drugs and treatment is the gamma distribution. The risk of adverse
211	reactions, and the health utility scores including PFS, OS, and AE are the beta distribution. We
212	performed a second-order Monte Carlo simulation of 10,000 iterations and generated a
213	cost-benefit acceptability curve (CEAC) to show that Nivolumab plus chemotherapy is
214	cost-effective with different WTP thresholds.
215	
216	

- 217
- 218

- 219
- 220
- 221
- 222
- 223 3. Results
- 224 3.1 Base-case Analysis

The result of base-case analysis about the cost and effectiveness of Nivolumab plus chemotherapy group and chemotherapy group in patients with untreated, unresectable advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma was shown in Table 1.According to our analysis,the incremental cost of Nivolumab plus chemotherapy(\$149636.97,1.24QALYs) verus chemotherapy(\$13941.06,0.75QALYs) is \$135695.91 and the QALYs is 0.49. The ICER values(\$276799.67) are higher than the United States's triple GDP per capita threshold in 2021 (\$207659).

232 3.2 Sensitivity Analyses

A one-way sensitivity analysis was used to test the robustness of the two population model

outputs. Under the condition that the input model parameters change by $\pm 20\%$, the influence of


- 235 each parameter on the analysis results is explored. The results are presented in the tornado diagram
- 236 (Figure 2). The sensitivity analysis results demonstrated that the cost of Nivolumab has the most

contributed to it.

238 3.3 Probability sensitivity analysis

Probability sensitivity analysis (PSA) is applied to test the bias of the multiple modelparameters on the analysis results when the multiple model parameters change simultaneously.

The results are presented through cost-effectiveness acceptability curves (Figure 3) and incremental cost-effectiveness scatterplots (Figure 4). According to the results, we found that the higher the average social willingness to pay, the higher the probability of Nivolumab plus chemotherapy producing the cost effect.Under the condition of a payment threshold of \$207659 per QALY, Probabilistic sensitivity analysis showed that there was 1.49% probability that Nivolumab plus chemotherapy was cost-effective within the fluctuation range of other model parameters in first-line in advanced gastric, GEJ, or oesophageal adenocarcinoma.



249 Figure 3. Acceptability Curves for the choice of sintilimab plus IBI305 versus sorafenib at

250 different WTP thresholds in patients in the treatment of hepatocellular carcinoma.

251 Abbreviation: WTP= Willingness to pay.






Figure4. Incremental cost-effectiveness scatterplots

255 We also conducted subgroup analysis of the patients with PD-L1 CPS according to 256 Median age (IQR),Race(Asian or Non-Asian),Region (Asia or United States and Canada or Rest of world), Primary tumour location at initial diagnosis (GC or GEJC or EAC), the value of Tumour 257 cell PD-L1 expression, Eastern Cooperative Oncology Group performance status(0 or 1), Prior 258 259 surgery(yes or no), the number of Organs with metastases, Signet ring cell carcinoma(yes or no), 260 Lauren classification (Intestinal type or Diffuse type or Mixed or Unknown), MSI status (MSS or 261 MSI-H or Not reported or invalid), Chemotherapy regimen (FOLFOX or XELOX), Disease stage (Metastatic or Locally advanced or Locally recurrent), Site of metastases (Liver 262 263 Or Peritoneum or CNS) according to the survival of subgroups of patients in CheckMate 649. Unfortunately, all subgroup analysis factors are all not likely to be cost effective when the payment 264 265 threshold Less than or equal to \$207659 per QALY.

267 4. Discussion

268	Fluoropyrimidine plus platinum-based chemotherapy is a first-line treatment for unresectable
269	advanced or metastatic human epidermal growth factor receptor 2 (HER2) negative gastric and
270	GEJ adenocarcinoma, but its efficacy is poor. The study subjects included in CheckMate 649 are
271	patients with advanced/metastatic gastric cancer/gastroesophageal junction cancer/oesophageal
272	adenocarcinoma with negative HER2. Nivolumab plus chemotherapy was compared with
273	chemotherapy to evaluate whether Nivolumab plus chemotherapy could be used as first-line
274	therapy for gastric/GEJ/oesophageal adenocarcinoma patients with negative HER2 .The result of
275	CheckMate 649 showed that Nivolumab plus chemotherapy had significantly improved median
276	survival time and median progression-free survival time compared to chemotherapy.Although
277	Nivolumab plus chemotherapy has considerable efficacy in patients with gastric/GEJ/oesophageal
278	adenocarcinoma, economic factors cannot be ignored. Many cancer patients are often forced to
279	ignore the most effective drugs for their treatment because of high drug prices and treatment costs.
280	Therefore, in order to avoid wasting medical resources, it is necessary to conduct a cost-benefit
281	analysis.
282	Based on CheckMate 649 clinical trials and the latest population data and drug prices in
283	USA, Our study is the first to evaluate whether Nivolumab plus chemotherapy is more
284	cost-effective than chemotherapy as first-line treatment for patients with gastric/GEJ/oesophageal
285	adenocarcinoma from the American payers' perspectives.We obtained the data of Nivolumab
286	plus chemotherapy group and chemotherapy group through the clinical trial CheckMate 649, so
287	we could only conduct cost-effectiveness analysis on these two groups. Our analysis shows that
288	with a WTP threshold of \$207659/QALY for the two groups ,the Nivolumab plus chemotherapy

289	group may not be cost-effective to be the first-line for gastric/GEJ/oesophageal adenocarcinoma.
290	We also performed subgroup analyses for all the subgroups mentioned in the clinical trials,
291	unfortunately, the subgroup analysis implied that Nivolumab plus chemotherapy was not a
292	cost-effective strategy across all the patient subgroups.
293	One-way sensitivity analysis demonstrated that reducing the cost of drugs was the most
294	influential factor to the result of cost-effectiveness. Since the therapeutic effect of the
295	experimental group was better than that of the control group, and chemotherapy was in the control
296	group, the price largely determines the cost-effectiveness. The lower the price of capecitabine,
297	oxaliplatin, leucovorin and fluorouracil, the lower the cost-effectiveness of the experimental
298	group. There also have been some economic studies on chemotherapy for gastric/GEJ/oesophageal
299	adenocarcinoma, but mainly compared with chemotherapy regimens such as FOLFOX and
300	XELOX. Chemotherapy is much less expensive than immunotherapy in most cases, so it is easier
301	to show cost-effectiveness. Another cost-benefit analysis of Atezolizumab and bevacizumab
302	combination compared with sorafenib in unresectable hepatocellular carcinoma also showed that
303	the immunotherapy group was not cost-effective compared to sorafenib alone(28). Therefore, We
304	conclude that PD-1 inhibitors may be difficult to recommend as cost-effectiveness options for
305	first-line recommendations in advanced gastric/GEJ/oesophageal adenocarcinoma.
306	We found that when the cost of Nivolumab plus chemotherapy was reduced by
307	23%, respectively, the ICER was \$207659 /QALY which was cost-effective. Therefore, changing
308	the price of Nivolumab plus chemotherapy is an effective feasible strategy to achieve efficient use
309	of them. medical insurance authority could negotiate with pharmaceutical companies to ensure

- reasonable drug prices and adjust the medical insurance list to reduce the medical burden on
 patients.

332 5.Limitations

333	Our study has some limitations. First, CheckMate 649 is a phase three randomised controlled
334	trial, and we used this model to simplify the study. For instance, regarding the adverse reactions,
335	we selected the three to four main AEs that would lead to errors. Second, the study's data
336	originated from the CheckMate 649 trial. Due to the limitation of the number of patients included
337	in the trial, we could not perform a larger-scale analysis, and the trial did not provide the
338	follow-up survival data for patients. We relied on the survival data based on the trial and
339	performed a reasonable extrapolation to predict the long-term survival of patients. This will
340	inevitably be different from the data of real-world patients obtained through regular follow-ups.
341	Third, since CheckMate 649 does not disclose the specific health data of patients, our PFS and PD
342	effectiveness were derived from previously published related studies. This may be different from
343	the actual situation of the study. Fourth, we only considered the cost impact and utility reduction
344	caused by the three to four main AEs. The utility reduction caused by specific adverse reactions
345	comes from other published literature, which is in line with the real situation. Fifth , the clinical
346	trial is a multicentred and comprehensive study between different countries and races. The
347	treatment plan of the trial, and especially the follow-up treatment of patients, will be adjusted
348	appropriately according to the specific situation. Therefore, more clinical trials are still required to
349	reduce the study population, follow-up treatment, and other factors that impact the results.
350	
351	
352	

353

354 6. Conclusion

- 355 Overall, from the Americans payers' perspectives, compared with chemotherapy, Nivolumab
- 356 plus chemotherapy a for the first-line treatment of patients aged 18 years or older who were
- 357 clinically or pathologically diagnosed with locally advanced or metastatic
- 358 gastric/GEJ/oesophageal adenocarcinoma may be not a cost-effective choice at a WTP threshold
- 359 of \$207659 /QALY.

376 Acknowledgements

377	The authors wish to acknowledge Dr Xiang-ping Li, Professor of Department of Pharmacy,
378	Xiangya Hospital, Central South University, for his help in tnterpreting the significance of the
379	results of the study.And also acknowledge Dr Qin Zhou, Professor of Department of Oncology,
380	Xiangya Hospital, Central South University, for support funding to this study.
381	Reference:
382	1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
383	2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
384	countries. CA Cancer J Clin. 2018;68(6):394-424.
385	2. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric Cancer,
386	Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National
387	Comprehensive Cancer Network : JNCCN. 2016;14(10):1286-312.
388	3. Gunderson LL. Gastric cancerpatterns of relapse after surgical resection. Semin Radiat
389	Oncol. 2002;12(2):150-61.
390	4. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric
391	cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of
392	oncology : official journal of the European Society for Medical Oncology. 2016;27(suppl
393	5):v38-v49.
394	5. Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The Chinese Society of
395	Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric
396	cancer. Cancer communications (London, England). 2019;39(1):10.
397	6. Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th

398 edition). Gastric Cancer. 2021;24(1):1-21.

399 7. Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al. 400 Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, 401 double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017;18(11):1467-82. 402 403 8. Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with 404 405 metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2019;20(3):420-35. 406 Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and 407 9. 408 cisplatin with or without cetuximab for patients with previously untreated advanced gastric 409 cancer (EXPAND): a randomised, open-label phase 3 trial. The Lancet Oncology. 410 2013;14(6):490-9. 411 10. Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of Fluorouracil, 412 Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive 413 Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol. 414 2017;3(5):620-7. 415 11. Ando K, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, et al. Nivolumab plus 416 Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced

417 Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Cancers
418 (Basel). 2020;12(7).

419 12. Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, et al. Axitinib,

420 cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated 421 renal cell carcinoma: a systematic review and economic evaluation. Health technology 422 assessment (Winchester, England). 2018;22(6):1-278. 13. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line 423 424 nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, 425 gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27-40. 426 427 14. Verma V, Sprave T, Haque W, Simone CB, 2nd, Chang JY, Welsh JW, et al. A 428 systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. 429 Journal for immunotherapy of cancer. 2018;6(1):128. 430 15. Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for Cured Patients in 431 Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(4):705-9. 432 433 16. Bullement A, Latimer NR, Bell Gorrod H. Survival Extrapolation in Cancer 434 Immunotherapy: A Validation-Based Case Study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(3):276-83. 435 436 17. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods in 437 molecular biology (Clifton, NJ). 2009;471:469-86. 18. Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, et al. Cost Effectiveness of 438 439 Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. PharmacoEconomics. 440 441 2017;35(8):831-44.

442	19.	Lin S, Luo S, Zh	ong	L, Lai S, Zei	ng D, Rao X, et	al. Co	st-effectiv	enes	s of	fatezo	olizumab
443	plus	chemotherapy	for	advanced	non-small-cell	lung	cancer.	Int	J	Clin	Pharm.
444	4 2020;42(4):1175-83.										

20. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al.
Recommendations for Conduct, Methodological Practices, and Reporting of
Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.
Jama. 2016;316(10):1093-103.

449 21. Thokala P, Ochalek J, Leech AA, Tong TJP. Cost-effectiveness thresholds: the past, the

- 450 present and the future. 2018;36(5):509-22.
- 451 22. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival
- data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med ResMethodol. 2012;12:9.
- 454 23. Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Cost-Effectiveness Analysis Of Ceritinib

And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive
 Advanced Non-Small Cell Lung Cancer. Cancer Manag Res. 2019;11:9195-202.

457 24. Zhang L, Zeng X, Cai H, Li N, Liu M, Qiu L, et al. Cost-effectiveness of second-line

458 nivolumab for platinum-treated advanced non-small-cell lung cancer. J Comp Eff Res.

459 **2020;9(18):1301-9**.

460 25. Wang X, Jin L, Cui J, Ma K, Chen X, Li W. Mouse double minute-2 homolog

- 461 (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese
- 462 population. Thoracic cancer. 2015;6(1):91-6.
- 463 26. Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness

- 464 analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer
- 465 Res Clin Oncol. 2017;143(2):361-8.
- 466 27. Ward MC, Shah C, Adelstein DJ, Geiger JL, Miller JA, Koyfman SA, et al.
- 467 Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol.
- 468 2017;74:49-55.
- 469 28. Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of
- 470 Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy.
- 471 2017;37(1):94-103.
- 472
- 473
- 474
- 475

476

477

478

479

480

- 482
- 483
- 484
- -10**-1**
- 485

- 486 487 488 489 490 491 Ethics approval 492 This study was based on a literature review and modelling techniques; this study did not require approval by an institutional research ethics board. 493 494 Disclaimer 495 The views expressed are those of the authors. The funding agencies played no role in the study 496 design, data collection and analysis, decision to publish, or manuscript preparation. 497 Provenance and peer review Not commissioned; externally peer reviewed. 498 499 Data sharing statement 500 No additional data are available. 501 Supplemental material 502 Supplemental material for this article is available online. 503 Figures and legends Figure1.Markov state transition model. 504 505 Figure2. Tornado diagram for one-way sensitivity analysis.
- 506 Figure3. Acceptability Curves.
- 507 Figure4.Incremental cost-effectiveness scatterplots.

- 508 Ethics approval and consent to participate
- 509 Not applicable
- 510 Consent for publication
- 511 Not applicable
- 512
- 513 Availability of data and materials
- 514 Data sharing is not applicable to this article as no datasets were generated or analysed during the
- 515 current study.
- 516 Conflict of interest
- 517 The authors declare that there is no conflict of interest.
- 518 Funding
- 519 This study was funded by the Natural Science Foundation of Hunan Province for Young Scholars
- 520 (No. 2020JJ5957; Project Recipient: QZ).
- 521 Authors' contributors
- 522 Mr Zhou and Mr Tang had full access to all of the data in the study and takes responsibility for the
- 523 integrity of the data and the accuracy of the data analysis.
- 524 Concept and design: Li.
- 525 Acquisition, analysis, or interpretation of data: Zhou, Tang.
- 526 Drafting of the manuscript: Zhou, Tang, Li.
- 527 Critical revision of the manuscript for important intellectual content: Tang.
- 528 Statistical analysis: Zhou, Tang.
- 529 Obtained funding: Zhou.

- 530 Administrative, technical, or material support: Zhou, Tang.
- 531 Supervision: Tang.